Researchers Identify Human Antibodies That Could Prevent and Treat Measles
In a significant breakthrough for public health, researchers have identified human antibodies capable of neutralizing the measles virus for the first time. This discovery marks a critical step toward the development of new prevention strategies and the world’s first dedicated treatment for one of the most contagious infectious diseases known to medicine.
The findings, published the week of May 4, 2026, in the journal Cell Host & Microbe, reveal that these specific antibodies attach to key regions of the virus, effectively blocking it from infiltrating host cells.
“These antibodies function as prophylaxis—to protect against the initial infection—and they also work after exposure to the virus as a treatment against the measles infection,” stated Erica Ollmann Saphire, the study’s coordinator from the La Jolla Institute for Immunology in California.
The path to this discovery began with the use of cryo-electron microscopy, an advanced imaging technique that allowed scientists to observe how antibodies from mice bound to the measles virus. Those earlier studies were instrumental in mapping the virus’s vulnerable points, providing a blueprint for the current research.
Building on that foundation, the research team isolated human antibodies from the blood of a woman who had been vaccinated many years prior. The study identified antibodies that target and inactivate the virus by binding to two critical regions: the measles fusion protein and a binding protein known as “H.”
This advancement is particularly vital as the medical community seeks more robust tools to combat measles outbreaks and protect vulnerable populations. The ability to neutralize the virus post-exposure could fundamentally change how healthcare providers manage the disease, moving beyond existing preventative vaccines to include active therapeutic interventions.
